Financial OutlookAnalyst reiterates a Buy rating with a bullish price objective, signaling confidence in NARI's stock growth potential and viewing recent share price decreases as a buying opportunity.
Leadership ChangeTim Benner brings extensive operational and strategic experience from large global companies to his new role as SVP of Sales at NARI, promising to enhance the company's strategic move to scale internationally.
Product And Market ExpansionNARI, a dominant force in the US venous thromboembolism market, is poised for continued growth driven by new product launches, the LimFlow acquisition, and international market penetration.